Drugs / aNK
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02465957 | Sep 2015 → Mar 2018 | cutaneous neuroendocrine carcinoma | ImmunityBio, Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | aNK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02465957 ↗ |
| Modality | Cell therapy | “A natural killer cell line recovered from a patient with large granular lymphoma” NCT02465957 ↗ |
| Route | Intravenous | “aNK will be given via IV infusion” NCT02465957 ↗ |